CytoREductive prostAtectomy for Poly-metastatic Hormone sensiTIVE Prostate Cancer

The goal of this clinical trial is to compare systemic therapy combined with cytoreductive prostatectomy with standard of care (SOC) in de novo poly-metastatic hormone sensitive prostate cancer (de novo pmHSPC). The main questions it aims to answer are: 1. To explore the clinical benefit and safety of systemic therapy combined with cytoreductive prostatectomy for patients with de novo pmHSPC. 2. To explore the characteristics of the subgroup of patients who could benefit more from the above treatment. 3. To explore the relationship between stage efficacy and clinical prognosis. 4. To explore

Trial Details

NCT ID
NCT06306612
Phase
NA
Sponsor
RenJi Hospital
Status
RECRUITING
Cancer Type
Hormone-Sensitive Prostate Cancer
Interventions
  • Systemic Chemohormonal Therapy
  • Systemic Hormonal Therapy
  • Cytoreductive Prostatectomy
  • Postoperative Adjuvant Radiotherapy
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Fully understand the purpose of this trial and sign a written informed consent;
  • Men aged 18-85 years;
  • have histologically or cytologically confirmed adenocarcinoma of the prostate;
  • Have multiple metastatic disease, defined as follows: according to RECIST v1.1, metastatic disease was defined as metastatic foci detected on bone …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Hormone-Sensitive Prostate Cancer Trials on Trialify →